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and C-reactin protein, that show lesser specificity (Fonfara et 
al 2010; Gu et al 2006; Saunders et al 2009; Shaw et al 2004; 
van Kimmenade & Januzzi 2009). This review will discuss the 
structure, metabolism, function, applicability, reference values 
and variations in different diseases of troponin I and N-terminal 
proBNP in dogs and cats. 
2. Cardiac biomarkers in small animal 
medicine
2.1. Troponin
Troponin (Tn) is a globular protein that binds the actin and 
miosin, regulating the striated muscle contraction. This pro-
tein exists under three different forms, TnI, TnT and TnC. The 
first two proteins, TnI and TnT are divided in two isoforms, 
depending on the muscle type they activate (cardiac and skel-
etal muscle) (O’Brien 2008). Cardiac troponin T (cTnT) and 
troponin I (cTnI) are myocardial regulatory proteins which are 
responsible for the control of the calcium binding between ac-
tin and myosin. Cardiac TnI has not been identified outside the 
myocardium while cardiac TnT can be found in small amounts 
in skeletal muscle, but in irrelevant quantity to crossover the 
assays (Bodor et al 1995; Ricchiuti et al 1998b; Sharma et al 
2004). Cardiac troponins are cardiomyocite injury specific bio-
markers (Liquori et al 2014). Cardiac injury induces myocyte 
distruction and membrane rupture, then the free cardiac tro-
ponin is released in the blood torrent in high concentrations. 
This process is followed by a slow and continuous release of 
structurally bound troponins, so explaining the sustained elevat-
ed serum concentration (Wells & Sleeper 2008). In dog serum, 
cTnI is detectable at 4-6 hours and peaked at 10-16 hours after 
an induced trauma (experimental miocardial infarction), faster 
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1. Introduction
National Institute of Health Biomarkers defined a biomarker, 
shortened term from biological marker, as a parameter which 
can be measured accurately, being an indicator of a normal or 
pathologic process, or a pharmacologic response to a therapeutic 
intervention (Strimbu & Tavel 2010; Wells & Sleeper 2008). In 
the clinical field, a reliable biomarker should respect some crite-
rias: first, it has to be easily measured, with available methods, 
prompt turnaround time and reasonable cost, second, to bring 
new and valuable information for the diagnostic or the treat-
ment efficiency, providing a strong and consistent association 
between the biomarker and the outcome, or disease of interest, 
and third, to help the clinician in managing the patient offering 
a superior performance to other diagnostic tests (Morrow & de 
Lemos 2007). A cardiac biomarker is a parameter that can pre-
dict or diagnose a cardiac disease either if it is primary or sec-
ondary with as high sensitivity and specificity as possible. The 
reason of the increasing interest in cardiac biomarkers is easy 
to understand. They are convenient, low cost, non-invasive, 
risk free, fast turn-around time, efficient and highly predictive 
tests (Drobatz 2009).
In the last 30 years many researchers have studied various types 
of cardiovascular markers, aiming to define better diagnostic 
aspects of primary and secondary cardiac diseases. In the vet-
erinary field, the most complete studies have been performed 
in small animals, mainly dogs and cats. 
At present, in veterinary clinical practice, the biomarkers with 
the highest predictibility for cardiac diseases are N-terminal 
pro-brain natriuretic peptide (NT-pro BNP) followed by cardiac 
troponins I and T (cTnI and cTnT), and less frequent used, atrial 
natriuretic peptide, endothelin, tumor necrosis factor α (TNF α) 
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than in humans. Serum cTnI was found elevated for up to 200 
hours after an induced trauma (Cummins & Cummins 1987). 
The increase in level of cTnT is relatively proportional to the 
degree of myocardial damage, with prognostic implications as 
well (Tarducci et al 2004). 
Normal ranges for cTnI are <0.03 – 0.07 ng/ml in healthy dogs 
and <0.03 -0.16 ng/ml in healthy cats, where the lower detect-
able limit for most of the tests is 0.02 ng/ml, and <0.05 ng/ml for 
cTnT in healthy dogs (Sleeper et al 2001; Tarducci et al 2004). 
Also, Oyama (2004) proposed the normal value 0.02±0.02 ng/
ml for cTnI in clinically healthy dogs (Oyama & Solter 2004). 
Troponin levels are determined by using human enzyme-linked 
immunosorbent-assay (ELISA) tests due to significant homol-
ogy in the proteins between species (Bodor et al 1992; Wells 
& Sleeper 2008). There are also two veterinary tests available 
for the cardiac troponin I (Oyama 2013).    
Although elevated cardiac troponin is highly sensitive for  myo-
cardial injury, this biomarker do not offer the possibility to dis-
tinguish between types of pathology, showing a low specificity 
(Oyama 2013). As recently implemented in small animal medi-
cine, in human medicine the cTnI assay is considered the gold 
method to assess the myocardial infarction, reported to have a 
97% sensitivity and 95% specificity (Alpert et al 2000; Wong 
1996). It was proved that the cTnI has a higher sensitivity in de-
tecting  the myocardial injury than cTnT (Linklater et al 2007).
In veterinary medicine, several studies had been performed for 
different pathologies involving myocardial damage, in order to 
establish the sensitivity and specificity of this biomarker,  and 
the value of the survival prediction (Fonfara et al 2010).   
A high concentration of cTnI has been found in dogs with mi-
tral valve disease (MVD) associated to intramyocardial arte-
riosclerosis and fibrosis (Falk et al 2013). One study on blood 
concentration of cardiac troponins had been performed in dogs 
with class IV (according to New York Heart Association classi-
fication) of congestive heart failure (CHF) due to MVD. Results 
showed that 40% of the dogs had detectable cTnI (median of 
0.24 ng/ml with a range between 0.12 – 0.31 ng/ml) and only 
7% had a detectable cTnT (0.02 ng/ml). Animals with detecta-
ble cTnI had a median survival of 67.5 days (range between 1 – 
390 days) comparing to non-detectable cTnI dogs with a median 
survival of 390 days (range between 20-912 days) (Linklater et 
al 2007). Oyama (2004) found a correlation between the con-
centration of serum cTnI and the left ventricle and  atrial size 
in dogs with MVD (Oyama & Sisson 2004). Cardiac troponin I 
can be used as a predictor for fibrosis in natural occuring chron-
ic cardiac disease, produced by various factors including toxic, 
metabolic, inflamatory or idiopatic origins. In the pathological 
changes described in heart failure due to mitral valve disease, 
arteriosclerosis is linked to fibrosis, the latter being almost in-
variably caused by ischemia (Falk et al 2013).
In dogs with occult dilated cardiomyopathy (DCM), significantly 
greater plasma concentration (0.21 ± 0.10 ng/ml) comparing to 
clinically normal group (0.06 ± 0.01 ng/ml) was found (Oyama 
et al 2007). Regarding Doberman Pinschers with overt DCM, 
cTnI serum concentrations were found significantly higher than 
those without clinical signs, and it was demonstrated that the val-
ues were relatively higher in subclinic patients which developed 
DCM within 1.5 years, concluding that cTnI serum concentrations 
can detect any form of DCM (Wess et al 2010).  Furthermore, 
cTnI serum levels correlated with left atrium and ventricle size 
(Oyama & Sisson 2004). Tarducci (2004) showed that cTnT is 
helpful in discriminating animals with myocardial damage in 
course from those in which hypokinesis is most likely indicative 
of a previous injury (Tarducci et al 2004). Finally, a study over 
Boxers with arrhythmogenic right ventricular cardiomyopathy 
(ARVC) showed that cTnI serum concentration was  increased 
comparing to clinically healthy group (Baumwart et al 2007).
An increase of cardiac troponin plasma levels have been found 
in dogs with pericardial effusion (PE). Patients with PE second-
ary to hemangiosarcoma (HAS) had a significantly higher se-
rum concentration of cTnI (median of 2.77 ng/dl with a range 
between 0.09 – 47.18 ng/dl) than those with idiopatic PE (me-
dian of 0.05 ng/dl with a range of 0.03 – 0.09 ng/dl). On the 
other side, no significant differences were found between se-
rum concentration of cTnT in dogs with HAS and those with 
idiopatic PE, and no correlation was found between the size 
of the mass and cardiac troponin concentrations (Shaw et al 
2004). Also Linde (2006) observed differences between cTnI 
serum levels in normal dogs (median of 0.03 ng/ml) and those 
with PE (0.19 ng/ml), but there were no differences between 
dogs with non-neoplastic PE and dogs with PE secondary to 
neoplasia (Linde et al 2006). A potential reason for this finding 
could have been the involvement of aggressive non-neoplastic 
lesions such as fungal pericarditis, chronic fibrous pericarditis, 
lymphocitic-plasmocytic pericarditis and bacterial pericardi-
tis, which can induce high troponin levels, similar to neoplas-
tic disease behaviour.
Serum concentration of cTnI was studied in dogs with var-
ied congenital heart diseases such as patent ductus arteriosus 
(PDA), subaortic stenosis (SAS), pulmonary stenosis (PS), and 
ventricular septal defect (VSD). There were no significant dif-
ferences between groups of healthy and affected dogs (Oyama 
& Sisson 2004; Spratt et al 2005). A modest correlation was 
found between cTnI concentration and ventricular wall thick-
ness (Oyama & Sisson 2004). CTnI serum levels have been 
evaluated before and after cardiac catheterisation in dogs pro-
posed for PDA coil embolisation, baloon valvuloplasty (BV) 
and pacemaker implantation. Dogs undergoing ovariohisterec-
tomy (OVH) have been used as control group in order to match 
the potential changes during anestesia. There was no significant 
difference between groups before surgery but significantly dif-
ferences were found after 5, 24 and 240 hours. The group with 
pacemaker implant had the greatest increase in cTnI while the 
smallest increase was found in PDA group (where the catheter 
did not touch the myocardium) (Shih et al 2009). Moreover, in-
creased plasma concentration have been found in animals with 
PS after performing the BV intervention (Saunders et al 2009). 
Higher concentration of cardiac troponin in most invasive sur-
gical intervention such as pacemaker implantation or BV con-
firm the direct relation between myocardial damage and blood 
concentration of troponin.   
Implications of parasitic diseases in cardiovascular pathology 
have also been assessed in several studies. Canine hearthworm 
disease (HWD) caused by Dirofilaria immitis produces an in-
crease in cTnI serum concentration due to the right heart myo-
cardial damage (Carreton et al 2012). Furthermore, it have been 
shown that cTnI serum concentration is increased in complicated 
stages of canine babesiosis (Lobetti et al 2002).   
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Table 1. Types of natriuretic peprides and their expression site 
(from Kimmenade & Januzzi 2009)
Atrial natriuretic peptide (ANP) and B-type natriuretic pep-
tide (BNP) have been found to be usefull in assessing the di-
agnostic of cardiac diseases, while the C-type natriuretic pep-
tide (CNP) expression is associated with the paracrine function 
and it also plays a role in the regulation of the vascular tone. 
Dendroaspis natriuretic peptide (DNP) and ventricular natriu-
retic peptide (VNP) have other utilities or exist in other species, 
such as VNP which have been found only in primitve ray-finned 
bony fish (Ciaramella et al 1995; De Luna et al 1992, 1993; 
van Kimmenade & Januzzi 2009). Atrial natriuretic peptide is 
found in atrial myocardium, while BNP is found in both atrial 
and ventricular myocardium, but in  higher concentration in 
the latter (Sudoh et al 1988; van Kimmenade & Januzzi 2009). 
B-type natriuretic peptide was proved to be more stable than 
ANP after release into the circulation. N-terminal fragment of 
the prohormone B-type natriuretic peptide (NT-pro BNP) is an 
inert molecule similar to active BNP molecule, both cleaved 
from the pro-BNP molecule (see Figure 1)(van Kimmenade & 
Januzzi 2009).
Figure 1.  Representation of the cleavage of proBNP (108 
amino-acids) into BNP (32 amino-acids) and NT-proBNP (76 
amino-acids)
With the same sensitivity and specificity as BNP, NT-pro BNP 
have the advantage of higher biological half-life (Fox et al 2009). 
The two fractions, BNP and NT-pro BNP have been used with 
success to assess the heart failure, acute coronary syndrome or 
ischemic cardiac disease, and also in guiding the heart failure 
therapy in human medicine and served as a model for veteri-
nary medicine. (Braunwald 2008; Januzzi et al 2005; Liquori 
et al 2014; Maisel et al 2002).
The prognosis of blunt chest trauma have been studied through 
cTnI and cTnT serum concentrations. In one study, results 
showed that cTnT was elevated in 9 of 33 comparing cTnI 
which was found elevated in 18 of 33 patients, concluding that 
cTnI is more specific than cTnT in predicting the severity of the 
injury (Schober et al 1999). Kirbach (2010) showed that cats 
with blunt thoracic trauma had a significant increase in blood 
cTnI concentration after 12 to 24 hours post trauma, which then 
graduately decreased. As in previous study, cTnT was found to 
be less specific than cTnI (Kirbach et al 2000).
Experimentally induced myocardial infarction in dogs showed a 
correlation between serum cTn concentration levels and the de-
crease of cTn in tissue concentration, due to post-lesional loss of 
cTn, showing the ability to predict the infarct size (Ricchiuti et al 
1998a). Exertional heatstroke can produce a severe myocardial 
damage ,increasing cardiac troponins plasma concentration. A 
case report in a dog stated that cTnI was extremely high (180 ng/
ml) and remained as high for over 16 days (Mellor et al 2006). 
Several studies over cTnI have have been performed in order to 
distinguish between cardiac and non-cardiac respiratory distress, 
although this test alone is not enough to establish an absolute 
diagnostic and generally further exams (such as diagnostic im-
aging) are required mostly because any systemic condition that 
cause hypoxiemia and myocardial ischemia can provoke eleva-
tion of circulating cardiac troponin (Connolly et al 2009a; Oyama 
2013). It was demonstrated that cTnI serum concentration can 
be used in diagnosis of hypertrophic myocardiopathy (HCM) 
in cats. Results showed a significantly higher concentration of 
serum cTnI in patients with HCM (median of 0.95 ng/ml with 
a range of 0.2-4.1 ng/ml) than in healthy patients (median < 0.2 
ng/ml with a range of 0.2 – 0.25 ng/ml) (Connolly et al 2003). 
Myocardial injury can be induced secondary to chronic exposure 
to excess of thyroid hormone in cats with hyperthyroidism, in-
creasing cTnI serum concentration (Connolly et al 2005). Also, 
cardiac troponins have been found in higher concentrations in 
some pathological conditions and diseases that, through their 
different pathogenetic mechanisms, might have implications 
in myocardial damage, such as marked anaemia, lymphoma, 
neoplasia, respiratory diseases, pancreatitis, Addison’s disease, 
Cushing syndrome, renal failure, and also in geriatric patients 
and predisposed but cardiac disease free dog breeds (Serra et al 
2010). The secondary patologies and their effect over the car-
dio-vascular phisiology must be always considered when per-
forming the interpretation of the assay,and should be correlated 
with other exams in order to increase the diagnostic accuracy. 
Finally, the aged heart, even when there is no proof of the pres-
ence of disease, can lose up to 35% of its total myocite number 
(Anversa et al 1990). The reason of this finding is unknown, 
but it may be related to degenerative changes and decrease in 
tisular perfusion (Ferrari et al 2003; Oxenham & Sharpe 2003).
2.2. Brain natriuretic peptide
Natriuretic peptides represent a class of hormones that control 
body fluid homeostasis through their natriuretic and diuretic ef-
fects, and exert influence over renin – angiotensin – aldosterone 
mechanism (Liquori et al 2014). Different types of natriuretic 
peptides are expressed in different tissues and different species, 
as seen in Table 1. 
Type of natriuretic 
peptide Expression
ANP Mainly atrial myocardium
BNP Mainly ventricular myocardium 
CNP Brain, endothelium, kidney, condrocytes, 
pituitary gland
DNP Venom gland of Dendroaspis angusticeps 
(Green Mamba)
VNP Heart of primitve ray-finned bonny fish 
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In veterinary medicine, sandwich enzime immunoassay tests 
(ELISA) are used to assess the NT-proBNP concentrations and 
normal and pathologic ranges in animals have been proposed: 
in dogs, a concentration of less than 900 pmol/l of NT-proBNP 
is not compatible with myocardial increased strech and stress, 
but more than 735 pmol/l in Doberman Pinschers indicates an 
increased risk for DCM, while in cats, a concentration less than 
100 pmol/l is not associated with cardiomyopathy, between 100-
270 pmol/l clinically significant cardiomyopathy is unlikely but 
early disease may be present, and more than 270 pmol/l suggests 
that clinically significant cardiomyopathy is present. 
Studies have been performed using NT-proBNP for assessing 
the cardiac disease and the severity degree in dogs with mitral 
valve disease and dilated cardiomyopathy compared to healthy 
dogs, showing that serum concentrations of NT-proBNP were 
higher in the affected ones. Furthermore, in dogs with cardiac 
diseases, serum levels of NT-proBNP were correlated with heart 
rate, respiratory rate, echocardiographic changes and renal func-
tion, concluding that NT-proBNP concentrations may be usefull 
in diagnosing cardiac diseases and also in the assessment of the 
severity grade (Oyama et al 2008).
 Significant difference was found among dogs in different class-
es of CHF according to the International Small Animal Cardiac 
Health Council (ISACHC), that showed a progressive increase 
of this biomarker according to the worsening of the hemody-
namic status. Furthermore a significant correlation was found 
between NT-proBNP concentration and left atrium/aorta (La/
Ao) ratio, suggesting that NT-proBNP is sensitive to intracar-
diac pressure due to volume overload (Piantedosi et al 2009).
 NT-proBNP have been studied in dogs with early stages of myx-
omatous MVD showing that plasma concentrations of natriuteric 
peptides were higher after reexamination (about 4 years later), 
correlated as well with the increase of mitral regurgitation jet. 
This proved that NT-proBNP can predict the progression of mi-
tral valve disease (Tarnow et al 2009). Another study showed a 
significant correlation between NT-proBNP concentration and 
regurgitation fraction, La/Ao ratio, shortening fraction and end-
diastolic left ventricular volume indexed to body surface area 
(EDVI). Moreover, NT-proBNP concentrations were found 
higher in dogs that underwent MVD decompensation within 12 
months (Chetboul et al 2009). Finally, an increase of 100 pmol/l 
of NT-proBNP plasma concentration would raise the mortality 
by 7%  in  dog with MVD (Moonarmart et al 2010).  
In a study that included 328 dogs with different stages of DCM, 
the diagnostic value of NT-proBNP  have been assessed show-
ing that NT-proBNP concentrations from all affected dogs  were 
significantly higher than healthy dogs. The sensitivity and spec-
ificity for all forms of DCM were found to be 81% and 75% 
using a 400 pmol/l cutoff (Wess et al 2011). Twenty-one dogs 
with occult DCM showed that  NT-proBNP concentration great-
er that 6.21 pg/ml had a sensitivity of 95.2% and a specificity 
of 61.9%, while the combination of NT-proBNP assay with 
24-hours Holter monitoring had a 94.5% sesitivity and 87.8% 
specificity, but BNP did not correlate with the dog’s age (Oyama 
et al 2007; Singletary et al 2012). A study regarding the impli-
cations in predictibility of mortality for dogs with heart failure 
due to DCM suggested that NT-proBNP concentrations could 
well correlate with the survival period, concluding that this bio-
marker could be useful in evaluation of the survival time in dogs 
(Noszczyk-Nowak 2011). Also, BNP plasma concentration was 
found higher in Boxers with arrhythmogenic right ventricular 
cardiomyopathy (ARVC) than healthy Boxers, but lower than 
dogs with other cardiac diseases, suggesting that BNP  may not 
be a good indicator  in these patients (Baumwart & Meurs 2005).
 NT-proBNP have been assessed in ischemic myocardial in-
farction. Experimentally induced myocardial infarction in dogs 
have shown to significantly raise the plasma concentration of 
NT-proBNP early post injury, and gradually decreasing over the 
next 28 days to baseline. NT-proBNP can be used as a helpful 
diagnostic indicator in asymptomatic acute and subacute myo-
cardial infarction (Hori et al 2012a). Allthough there is no study 
in natural occuring cardiac hypertrophy, serum concentrations 
of NT-proBNP have been assessed in dogs with induced con-
centric hypertrophic cardiomyopathy by aortic constriction, 
creating a model of natural aortic stenosis. Results showed that 
NT-proBNP levels were significantly higher 3 to 6 months post 
aortic constriction demonstrating the utility of NT-proBNP in 
identifying early ventricular remodelling due to pressure over-
load (Hirata et al 2001; Hori et al 2008). Also, experimentally 
induced embolic pulmonary hypertension have shown impli-
cations in NT-proBNP plasma concentration due to right ven-
tricular myocardial stretch and remodelling. A study showed 
that NT-proBNP concentration increase significantly in severe 
chronic pulmonary hypertension, but not in mild pulmonary hy-
pertension, suggesting correlation between NT-proBNP concen-
tration and myocardial remodelling in chronic right ventricular 
pressure overload (Hori et al 2012b). 
Many studies have been performed over the potential of BNP 
in distinguishing between the cardiac and respiratory diseases. 
One study assessed BNP concentration to distinguish between 
cardiac and non-cardiac dyspnea. Twenty-two dogs with dys-
pena due to congestive heart failure and twenty-six dogs with 
non-cardiac dyspnea have been subjected to the study show-
ing a higher BNP concentration in dogs with congestive heart 
failure (mean of 34.97 pg/ml) comparing to non-cardiac dogs 
(mean 12.8 pg/ml) (Prosek et al 2007). A second study used 
NT-proBNP to distinguish between cardiac and non-cardiac 
dyspnea, with the same results. Furthermore, it was shown that 
increased creatinine is associated with NT-proBNP concentra-
tion, suggesting that this is a usefull marker for diagnosing car-
diac diseases, but the interpretation must be made in the light 
of patient’s renal function (Boswood et al 2008). In hyperten-
sive cats with chronic kidney diseases the NT-proBNP plasma 
concentration was found significantly higher. Also, there have 
been found significant differences between non-hypertensive 
cats with chronic kidney disease and normal cats, highlightning 
the effect of renal function alteration over BNP blood concen-
tration (Lalor et al 2009). The BNP concentrations in dogs di-
agnosed with congestive heart failure presenting either cough 
or dyspnea were found correlated with the disease severity 
(DeFrancesco et al 2007).
Golden Retreiver dogs with occult phase of muscular dystrophy 
cardiomyopathy were found to have higher concentrations of 
BNP (mean±SD of 117±92 pg/ml) than healthy dogs (mean±SD 
of 46±22 pg/ml) (Chetboul et al 2004). Moreover, NT-proBNP 
have been assessed in babesiosis with different degrees of sever-
ity showing different concentrations among groups, suggesting 
Baisan et al 2016
Volume 8 | Issue 1 Page 54 
HVM Bioflux
http://www.hvm.bioflux.com.ro/
that NT-proBNP concentration can predict the severity of the 
disease and the induced cardiac stress (Lobetti et al 2012). 
Finally, several studies have been performed to assess the clini-
cal implications of BNP in feline cardiac diaseses. Plasma con-
centration of NT-proBNP have been tested in cats with severe 
hypertrophic cardiomyopathy showing increased concentra-
tions in affected cats comparing to healthy ones. On the con-
trary, there was no statistical difference between the concentra-
tion of NT-proBNP in affected and normal cats, suggesting that 
this assay has a high sensitivity and specificity in detecting only 
cats with severe hypertrophic cardiomyopathy (Hsu et al 2009). 
B-type natriuretic petide concentration differences have also 
been studied between cardiac and non-cardiac cats with dysp-
nea. One study of 167 dyspneic cats, 101 cardiac and 66 non-
cardiac, showed that NT-proBNP concentration was higher in 
cats with congestive heart failure (median of 754 pmol/l) than 
non-cardiac cats (median of 76.5 pmol/l) (Fox et al 2009). Also, 
in a study of 74 cats with respiratory distress, 33 cats with CHF 
and 41 non-cardiac cats, was shown that those with CHF had 
higher NT-proBNP serum concentration (median of 523 fmol/
ml) than non-cardiac ones (median of 45 fmol/ml) (Connolly et 
al 2009b). A low NT-proBNP concentration is more often asso-
ciated with a non-cardiac disease, whereas an elevated concen-
tration is more suggestive of CHF (Oyama 2013). Moreover, 
pleural fluid NT-proBNP concentrations were found strongly 
correlated with  levels of NT-proBNP in both plasma and pleu-
ral fluid and were significantly higher in cats with pleural effu-
sion secondary to cardiac disease than those with non-cardiac 
disease (Humm et al 2013). 
The implications of cardiac troponin I and B-type natriuretic 
peptides in cardiac and non-cardiac diseases in small animals 
are shown in Table 2.
2.3. Other cardiac biomarkers used in domestic carnivores
The first studies on cardiovascular markers date back to 1980s 
when one of the first described cardiac biomarker was endothelin 
(ET), a peptide hormone isolated from the aortic porcine cells 
(Yanagisawa et al 1988). There were described three distinct iso-
forms: endothelin-1, endothelin-2 and endothelin-3 (Inoue et al 
1989). Its patophysiological importance is reflected by the plas-
ma level concentration during cardiovascular and renal diseases 
(Clavell et al 1993). The main biological effects of endothelin 
is the induction of vasoconstriction, mainly in the venous, but 
also in the arterial sector, with marked action on the pulmonary, 
renal and mesenteric circulation, and also the inotropic modu-
lation and myocardial hypertrophy development (De Luna et 
al 1994; Ito et al 1991; Moravec et al 1989). In compare with 
other hormones, endothelin has a slow and prolonged effect in 
time over the cardiocirculatory system (De Luna et al 1994). 
This biomarker have been used to assess cardio-circulatory dis-
eases in veterinary medicine, but with lower diagnostic value 
than other markers. Endothelin and Big endothelin-1, the cir-
culating form of endothelin, were used in diagnosing dogs with 
dilated cardiomyopathy, congestive heart failure, myocardial is-
chemia, and in distinguishing between cardiac and non-cardiac 
diseases (Cavero et al 1990; Liu et al 1990; Prosek et al 2004a; 
Prosek et al 2004b; Prosek et al 2007; O’Sullivan et al 2007). 
Piantedosi (2009) used endothelin along with other biomark-
ers to assess the hemodynamic status and the class of conges-
tive heart failure  in dogs with chronic degenerative valvular 
disease (Piantedosi et al 2009).
In 1981, de Bold discovered the effect of atrial natriuretic peptide 
(ANP), by injecting atrial tissue extracts intravenously and pro-
ducing diuresis and natriuresis in rats (de Bold et al 1981). One 
of the first studies in veterinary medicine on this biomarker was 
performed in 1991 by Takemura by assessing its concentration 
Cardiac troponins B-type natriuretic peptide
Mitral valve disease Dog Mitral valve disease Dog
Dilated cardiomyopathy Dog Dilated cardiomyopathy Dog
Pericardial effusion (neoplastic and non-
neoplastic) Dog Arrhythmogenic right ventricular myocardiopathy in Boxers Dog
Baloon valvuloplasty in pulmonary stenosis Dog Myocardial infarction (induced) Dog
Cardiac catheterisation and pacemaker implantDog Concentric hypertrophy (induced) Dog
Distinguish between cardiac and non-cardiac 
respiratory distress
Cat Pulmonary hypertension (induced) Dog
Hypertrophic cardiomyopathy Cat Distinguish between cardiac and non-cardiac dyspnea
Dog
Cat
Cardiomyopathy due to hyperthyroidism Cat Distinguish between cardiac and non-cardiac respiratory diseases
Dog
Cat
Heartworm disease Dog Congestive heart failure with signs of cough or dyspnea Dog
Babesiosis Dog Occult phase of muscular dystrophy cardiomyopathy in Golden 
Retreiver
Dog
Blunt chest trauma
Dog
Distinguish between cardiac and non-cardiac pleural effusion Cat
Cat
Myocardial infarction (induced) Dog Systemic hypertension Cat
Exertional heatstroke Dog Babesiosis Dog
Table 2. The use of cardiac troponins and B-type natriuretic peptides in different cardiac and non-cardiac pathologies
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level in dogs with mitral valve regurgitation (Takemura et al 
1991b). Atrial natriuretic peptide is a 28 amino acid polypep-
tide cleaved from proANP precursor, produced in the atrial 
wall secondary to myocardial tension due to pressure over-
load.(Ackerman et al 1992; Levin et al 1998; van Kimmenade 
& Januzzi 2009). For a long time ANP was used in veterinary 
medicine to assess cardiac diseases such as mitral valve disease, 
proving to be discriminating between stages of heart failure, also 
in dilated cardiomyopathy, heartworm diasease, and in distin-
guishing between cardiac and non-cardiac diseases (Boswood 
et al 2003; Haggstrom et al 1994; Prosek et al 2007; Takemura 
et al 1991a; Tidholm et al 2001; Vollmar et al 1991). 
Creatine kinase (CK) and its fraction CK-MB are also bio-
markers used to assess the cardiac function in different types 
of pathologies or surgery techniques developing myocardial 
damage, such as ischemia, myocardial necrosis or percutane-
ous coronary intervention in humans (Apak et al 2005; van der 
Vleuten et al 2008). This biomarker is not specific to myocardial 
tissue, being released also during non-cardiac muscle damage 
(Norris et al 1979). Apak  (2005) concluded that cardiac tro-
ponin T is a more specific and sensitive marker for myocardial 
injury than CK-MB.  
3. Perspectives and conclusions
The biomarkers represent a new step in both, veterinary and hu-
man medicine diagnostic methods, with the major advantages 
of precision and non-invasiveness. These new tests can help 
the clinician to formulate a correct diagnosis. One of the most 
revolutionary discovery in cardiac biomarkers was the BNP ca-
pacity to distinguish between dyspnea due to cardiac and non-
cardiac pathology. The assay for this purpose was rapidly con-
sidered as a gold standard method in human medicine, raising 
the interest of many researchers also in veterinary medicine. 
Despite this, the biomarkers are not stand-alone tests and their 
results should be evaluated in the context of the medical history, 
physical examination and other diagnostic tests. The biomarkers 
discussed in this paper are the most used for assessing cardiac 
condition, with diagnostic potential in most pathologies, but re-
liability is still lacking and further researches are required. As 
previous seen, cardiac troponins have implications in myocar-
dial tissue damage, necrosis, fibrosis, ischemia, and cell death 
with the potential of orientating the gravity of the injury and 
the elapsed time, allthough they do not offer any information 
regarding the mechanism of the injury. Natriuretic peptides are 
more specific to assess myocardial stress and strech due to vol-
ume overload, but without tissue damage, and furthermore im-
plications in cardio-vascular therapy. These pathophysiological 
mechanisms, alone or associated, are representative for most 
of the cardiac pathological conditions, offering the posibility 
to diagnose the disease through biomarker assay. It was dem-
onstrated in many studies that cTnI is more specific than cTnT, 
showing higher plasma concentrations in affected patients, but 
the reason for this finding is unknown. A potential explana-
tion could be a more powerful structurally binding of the cTnT 
with the tropomyosin chain. B-type natriuretic peptide  has the 
ability of diagnosing myocardial stress long before the onset 
of the clinical signs, making it a very important tool for the oc-
cult cardiopathies such as dilated cardiomyopathy. Two of the 
most important requirements that typify the biomarkers are 
sensitivity and specificity. Future researches should improve 
these aspects to obtain diagnostic tests always more indicative 
of clinical status of the patients.   
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